We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+45.54%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$132M
AUM Growth
-$48M
Cap. Flow
-$51.8M
Cap. Flow %
-39.17%
Top 10 Hldgs %
58.69%
Holding
110
New
19
Increased
5
Reduced
6
Closed
42

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$9.06M
2
GRI
GRI Bio
GRI
+$8.89M
3
IMGN
Immunogen Inc
IMGN
+$5.73M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$4.5M
5
JSPR icon
Jasper Therapeutics
JSPR
+$4.26M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$8.15M
2
ACLX
Arcellx
ACLX
+$4.62M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$4.58M
4
GKOS icon
Glaukos
GKOS
+$4.56M
5
PEN icon
Penumbra
PEN
+$4.46M

Sector Composition

Rank Sector Weight
1 Healthcare 92.25%
2 Financials 1.18%
3 Technology 1.18%
4 Communication Services 0.44%
5 Materials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGVC
101
DELISTED
TG Venture Acquisition Corp. Class A Common Stock
TGVC
– –
-200,000
Closed -$2.07M
THRX
102
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-112,614
Closed -$1M
NSTG
103
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-225,992
Closed -$2.24M
NVTA
104
DELISTED
Invitae Corporation
NVTA
– –
-409,200
Closed -$552K
ISEE
105
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-130,000
Closed -$3.16M
BLU
106
DELISTED
BELLUS Health Inc.
BLU
– –
-1,132,000
Closed -$8.15M
EUCRW
107
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
– –
-133,333
Closed -$4.82K
PBLA
108
DELISTED
Panbela Therapeutics, Inc. Common Stock
PBLA
– –
-559
Closed -$148K
CTIC
109
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-850,000
Closed -$3.57M
RACYW
110
DELISTED
Relativity Acquisition Corp. Warrant
RACYW
$0 ﹤0.01%
100,000
– –
1 2 3 4
5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return

Altium Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Altium Capital Management held 110 positions worth $132M, down 27% from $180M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Altium Capital Management withdrew a net $51.8M in Q2 2023, closing 42 positions and reducing 6 holdings. Its most notable exit was BELLUS Health Inc., an estimated $8.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Financials and Technology.

Against the trend, Altium Capital Management opened a new position in Xenon Pharmaceuticals worth $8.78M.

  • Altium Capital Management's largest Q2 2023 buy was Xenon Pharmaceuticals: 228,000 shares worth $8.78M.
  • Altium Capital Management added most to Harmony Biosciences in Q2 2023, an estimated $4.14M increase.
  • Altium Capital Management's biggest Q2 2023 reduction was ADMA Biologics, cutting an estimated $1.82M.
  • Altium Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $8.15M.
  • Altium Capital Management's ten largest holdings make up 59% of its $132M portfolio in Q2 2023.
  • Altium Capital Management opened 19 new positions and closed 42 in Q2 2023.
  • Altium Capital Management's portfolio value fell 27% quarter-over-quarter to $132M.

Based on Altium Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.